Performance History
| Key Stats | |
|---|---|
| Open | $44.16 |
| Prev. Close | $43.85 |
| EPS | -8.25 |
| Dividend | Non-Dividend |
| Next Earnings Date | - |
| Dividend Yield % | - |
| Market Cap | $3.61B |
| PE Ratio | - |
| LOW | HIGH | |
|---|---|---|
| Day Range | 43.71 | 44.57 |
| 52 Week Range | 31.52 | 54.98 |
| Ratios | |
|---|---|
| P/B Ratio | 14.05 |
| Revenue | $434.24M |
| Operating M. % | -95.81% |
| Earnings | $0.00 |
| Earnings Growth % | 14.25% |
| EBITDA Margin % | -125.09% |
| ROE % | -193.23% |
| EPS | -8.25 |
Score Breakdown
Welcome to Stocklytics
Don't miss out on the opportunity to stay ahead in the ever-changing world of finance.
All Score 59 / 100 is to help users identify stocks that trade at a low value relative to their fundamentals. Suitable for value investors such as Warren Buffet.
| RARE | MARKET | |
|---|---|---|
| Value | 32 | 40 |
| Quality | 54 | 40 |
| Ownership | 2 | 17 |
| Growth | 53 | 43 |
| Dividends | - | 38 |
Ultragenyx Pharmaceutical 's Sales growth rate in the last 3 years of 11.46% is modest compared to market average of 17.45%. This indicates RARE could be a bad value stock.
Financial Forecast
AI Price Prediction
Analyst Ratings
Correlated Companies
About Ultragenyx Pharmaceutical (RARE)
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Dr. Emil D. Kakkis M.D., Ph.D.
- Headquarters
- Novato
- Employees
- 1311
- Exchange
- NASDAQ
Keep an eye on Ultragenyx Pharmaceutical
Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.
Frequently Asked Questions
What is Ultragenyx Pharmaceutical 's (RARE) price per share?
The current price per share for Ultragenyx Pharmaceutical (RARE) is $44.24. The stock has seen a price change of $0.39 recently, indicating a 0.89% change. This reflects the stock's recent market performance and investor sentiment.
What is the 52-week high and low for Ultragenyx Pharmaceutical (RARE)?
For Ultragenyx Pharmaceutical (RARE), the 52-week high is $54.98, which is 24.28% from the current price. The 52-week low is $31.52, the current price is 40.36% above the 52-week low. This gives investors an insight into the stock's volatility and price range over the past year.
Is Ultragenyx Pharmaceutical (RARE) a growth stock?
Ultragenyx Pharmaceutical (RARE) has shown an average price growth of -24.34% over the past three years. It has received a score of 23 out of 100 based on the Stocklytics formula. The interpretation of this score in terms of classifying Ultragenyx Pharmaceutical as a growth stock may vary, considering it is one of many factors investors might evaluate, including market trends, financial performance, and future prospects of the company.
What is Ultragenyx Pharmaceutical (RARE) stock price performance year to date (YTD)?
As of the latest data, Ultragenyx Pharmaceutical (RARE) has a year-to-date price change of -8.16%. Over the past month, the stock has experienced a price change of -2.68%. Over the last three months, the change has been -1.62%. Over the past six months, the figure is 28.19%. Looking at a longer horizon, the five-year price change stands at -35.27%.
Is Ultragenyx Pharmaceutical (RARE) a profitable company?
Ultragenyx Pharmaceutical (RARE) has a net income of -$606.64M, which represents the company's total earnings after all expenses have been deducted from revenues. The gross margin of 89.59% indicates the percentage of revenue that exceeds the cost of goods sold, and the operating margin of -95.81% reflects the percentage of revenue remaining after covering variable production costs, highlighting the efficiency of the company's core operations. Total revenue stands at $434.25M, with a revenue growth rate of 19.52%, providing insight into the company's sales performance and growth. The gross profit is $389.04M. Operating income is noted at -$569.21M. Furthermore, the EBITDA is -$543.2M.
What is the market capitalization of Ultragenyx Pharmaceutical (RARE)?
Ultragenyx Pharmaceutical (RARE) has a market capitalization of $3.61B. The average daily trading volume is 798.68K, indicating the stock's liquidity and investor engagement.
News
Meta Platforms Stock: Is it a Buy on the Dip?
Natural Language Processing Market Size to Cross the $150B Mark by 2030
The Worst Performers Among Top Cryptos: Polygon and Cardano Brought Losses to 86% and 61% of Investors in 2024
Bitcoin’s 124% 10-Year Annualized Return Tops S&P 500 and Gold, Best Asset of the Decade
Tesla Stock Surges in After-Hours Trading as Company Accelerates Launch of Affordable Vehicles
Digital Wallets to Make 46% of all POS Transactions by 2027
Sign up for our newsletter
Join our exclusive community of over one million investment enthusiasts and receive our free newsletter filled with analysis, news, and updates every weekday.